39 Nexium Bone Density Suits Consolidated By MDL Panel

Law360, New York (December 6, 2012, 7:58 PM EST) -- The U.S. Judicial Panel on Multidistrict Litigation on Thursday consolidated 39 suits claiming the AstraZeneca LP heartburn drug Nexium causes bone density loss, shooting down the pharmaceutical company's argument that distinct causation and product identification questions justify keeping the cases separate.

AstraZeneca argued that discovery would require looking into each product's regulatory history and clinical trials and said proving a link between taking Nexium and the alleged bone density loss would also require specific expert reports depending on the type of injuries claimed. Those potential issues,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.